AU2021104471A4 - Botanical Compositions - Google Patents
Botanical Compositions Download PDFInfo
- Publication number
- AU2021104471A4 AU2021104471A4 AU2021104471A AU2021104471A AU2021104471A4 AU 2021104471 A4 AU2021104471 A4 AU 2021104471A4 AU 2021104471 A AU2021104471 A AU 2021104471A AU 2021104471 A AU2021104471 A AU 2021104471A AU 2021104471 A4 AU2021104471 A4 AU 2021104471A4
- Authority
- AU
- Australia
- Prior art keywords
- skin
- composition
- acne vulgaris
- treatment
- callistemon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 206010000496 acne Diseases 0.000 claims abstract description 58
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 50
- 230000000699 topical effect Effects 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 23
- 239000004615 ingredient Substances 0.000 claims abstract description 19
- 241001264766 Callistemon Species 0.000 claims abstract description 17
- 230000012010 growth Effects 0.000 claims abstract description 10
- 230000009467 reduction Effects 0.000 claims abstract description 6
- 241000378467 Melaleuca Species 0.000 claims abstract description 3
- 239000003921 oil Substances 0.000 claims description 23
- 239000006071 cream Substances 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000000419 plant extract Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000010773 plant oil Substances 0.000 claims description 11
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 241000010789 Callistemon lanceolatus Species 0.000 claims description 5
- 244000163122 Curcuma domestica Species 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- 241001278097 Salix alba Species 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 235000006468 Thea sinensis Nutrition 0.000 claims description 4
- 241000329467 Thymus quinquecostatus Species 0.000 claims description 4
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 4
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004889 salicylic acid Drugs 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 244000148064 Enicostema verticillatum Species 0.000 claims description 3
- 206010027626 Milia Diseases 0.000 claims description 3
- 235000003373 curcuma longa Nutrition 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- -1 pomade Substances 0.000 claims description 3
- 229940055019 propionibacterium acne Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 235000014375 Curcuma Nutrition 0.000 claims description 2
- 244000164418 Curcuma xanthorrhiza Species 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010037888 Rash pustular Diseases 0.000 claims 1
- 244000223014 Syzygium aromaticum Species 0.000 claims 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000029561 pustule Diseases 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 18
- 210000002374 sebum Anatomy 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 241000219926 Myrtaceae Species 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 241000134886 Myrtales Species 0.000 abstract 1
- 241001264734 Callistemon viminalis Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 11
- 229940100611 topical cream Drugs 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 239000000598 endocrine disruptor Substances 0.000 description 3
- 239000001902 eugenia caryophyllata l. bud oil Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000366182 Melaleuca alternifolia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000003393 Curcuma xanthorrhiza Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002910 effect on acne Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000901 systemic toxic effect Toxicity 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to compositions comprising of botanical extracts prepared from the Callistemon
species, also known as the Melaleuca genus or the order Myrtales from the Myrtaceae family. The
compositions comprise of combinations thereof, specifically selected ingredients for topical
applications to stop the growth of P. acnes, also known as C. acnes and a treatment of acne vulgaris.
The composition is effective as a control of excessive sebum production and the reduction of skin
redness, prone to inflammation.
Description
2021104471
Title: Botanical Compositions
Technical specifications The disclosure relates to the use of compositions comprising of specific botanical ingredients and combinations thereof, in a topical formulation for the control and treatment of acne vulgaris, reduction of excessive sebum production and reduction of skin inflammation.
Background One of the most common skin conditions that effect individuals between the ages of 15 and 45 years of age, is acne vulgaris. There is no specific ethnicity or genetic phenotype that has a significant characteristic advantage over the control and elimination of this skin disorder. Consequently, this acne vulgaris affects both sexes although, male hormones have been shown to exacerbate the condition. Collectively, this is a prominent and leading problem on a global scale. Acne vulgaris is a skin malady that results in either an obstruction of the sebaceous follicle glands, or an excessive overproduction of sebum by glands in skin.
Furthermore, the sebum is used as a food source for the growth of the bacterium called Propionibacteriumacnes, also known as Cutibacteriumacnes. In addition, skin obstructions result in the formation of whiteheads (where the follicle is blocked, and the skin surface is sealed) or blackhead comedones (where the skin is flared and turns black due to the presence of melanin). This collectively contributes and causes redness and inflammatory lesions in the skin. For example, the trapped sebum in the skin supports the growth for bacterial P. acnes. This is because it supportively creates a provision of anaerobic microenvironment for P. acnes to reside and grow in, due to the lack of oxygen, and pro-inflammatory mediators. Consequently, the formation of acne vulgaris results. This is reflective on an individual's skin.
Subsequent years of research, the inventors have identified for the first time, a combination of natural botanical extracts, oils, or conditioned water from the Callistemon species, in specific, Callistemon viminalis, also known as Melaleuca viminalis, and combinations therefore, with selected ingredients, is an outstanding treatment of acne vulgaris.
The Callistemon viminalis is an evergreen shrub, or small tree that belongs to the myrtle family with species frequently known as the weeping or crimson bottlebrush, Melaleuca viminalis or Myrtaceae.
The inventors have identified that the essential oils possess properties that behave as antimicrobials, with anti-inflammatory aspects against P.acnes. In fact, in China, the Callistemon species, chiefly C. viminalis is used in traditional Chinese medicine for treating haemorrhoids.
The biological activity of an essential oil is not usually ascribed to a single constituent however, it is rather about the synergistic properties of the phyto-complex combinations. Moreover, its chemical complexity donates to its biological actions since each constituent of the phyto-complex contribute towards the overall activity or can modulate the effects of the other constituents.
The Callistemon species has lanceolate leaves and a characteristic that reflects a 'bottlebrush' shaped flower spikes with protuberant red stamens, hence, commonly named bottlebrush. One of the most cultivated members of this genus is C. citrinus, usually identified as Crimson or Lemon Bottlebrush. The callistemon species produce essential oils. In folk medicine, Callistemon is well recognized for its insecticidal, as well as its anti-cough and anti-bronchitis activities. However, its effect on acne remains unknown and totally unexplored. This invention has identified for the first time, that the applied Callistemon total essential oils, water or total extract has potent anti-acne, anti-inflammatory, and anti proliferative activities, against p. acne.
The medicinal properties of Callistemon viminalis have been used traditionally used for hundreds of years by several different cultures around the world, for various herbal medicine applications. Numerous studies have shown that Callistemoncan modulate numerous targets such as cytokines, enzymes, growth factor receptors, transcription factors, and genes that regulate cellular apoptosis. These are several-fold and include relief of inflammatory conditions, digestive disorders, arthritic and skin conditions, cancers, and neurodegeneration, to name a few.
Succeeding years of research, the inventors have identified for the first time that Callistemon viminalis and its chemical signature and characteristic difference can be used for specific topical applications. The main molecular difference is a its expression of a high amount of the active ingredients that influence p. acnes.
In an embodiment the inventors have discovered and demonstrated the use of Callistemon viminalis total extract, oil or water has a minimum inhibitory concentration activity and anti-microbial activities against Propionibacteriumacnes (P. acnes).
In an embodiment the inventors have also demonstrated that using Callistemon viminalis prepared total extracts (entire plant extract) and oils prepared have superior minimum inhibitory concentration activity and anti-microbial activities against P. acnes, compared to antibiotics.
In another embodiment the inventors have discovered and demonstrated that the Callistemon viminalis total extract, oil or water can be used in topical applications for the treatment of acne vulgaris.
In yet another embodiment the inventors have discovered and demonstrated that when Callistemon viminalis total extract is prepared alone, or its oil are greater and more efficacious in inhibiting the growth of P. acnes.
In an additional embodiment the inventors have discovered that the Callistemon viminalisprepared total plant extract, oil or water have microbial inhibitory activity and demonstrated that the Callistemon viminalis total plant extract or oils are superior in the treatment of acne vulgaris.
In another additional embodiment the inventors have compared the Callistemon viminalis plant extract, oil and water using the minimum bactericidal concentration methodology and demonstrated that the Callistemon viminalis extract, oil and water can inhibit the growth of P. acnes and colony forming units (CFU) by the killing of P. acnes.
Based on the current evidence there is an immense advantage and potential of using the Callistemon viminalis total extract (TA), Callistemon viminalis oil or water of Callistemon viminalis for the development of cosmetic products to eliminate P. acnes and the treatment of acne vulgaris. This natural formulation is safer for the consumer, compared to chemical-based formulations that can have detrimental effects on people particularly the growing bodies of teenagers, when their compositions contain harsh and toxic endocrine disrupting chemicals.
This discovery has been translated into the innovation by the formulation of a composition that includes the total extract or its oil or water from Callistemon viminalis for use in topical applications in the form of creams, oils, emulsions, gels, ointments, pomades, soaps, lotions, serums, skin conditioners, skin toner, skin cleansers, for the treatment of acne vulgaris. Hence, in order to solve the disadvantage of the prior art, the object of a preferred embodiment of the present invention is to provide a safer, non toxic composition that clears acne.
In an embodiment the inventors have identified a composition comprising of a combination of the said Callistemon viminalisprepared TA or oil that stop the growth of P. acnes is also effective against sebum control and the calming of inflammation.
The invention is a result from years of research to identify herbal (natural) medicines that possess anti inflammatory and anti-bacterial properties that can be incorporated into cosmeceutical products for topical application for the control and treatment of acne vulgaris.
Although there are several available treatments for acne vulgaris, they are insufficient and don't address the specific requirements that are dependent on the type of clinical lesion of the skin. For example, topical retinoids are generally used against comedone induced acne. Others such as hormonal therapies or the use of isotretinoin are also readily prescribed as acne treatments. Topical antibiotics such as erythromycin, tetracycline or topical benzoyl peroxide are also readily used. However, these can potentially have devastating anatomical skin consequences resulting in severe skin dryness, induce skin flaking and shedding, systemic toxic effects, and psychological consequences. Other methods include the use of surgical treatments such as photodynamic therapy (PDT), cryotherapy or microdermabrasion.
Another common method is the use of alpha hydroxyl acids which make skin worse before having any beneficial effect. The use of sodium lactate, boric acid is also readily used; however, these are less desirable since they cause itching and redness on sensitive skin. Triclosan is also found in many well known products. This is a well-known endocrine disrupting chemical (EDC) that is readily used in many different personal and skincare products and has severe consequences. In fact, the Food and Drug Administration of the United States has banned the use of this constituent in such applications.
Collectively, although these methodologies and ingredients are readily available in products, and they evidently have disadvantages, do not effectively have a rapid onset for the control of acne, or are unsafe for the consumer.
There is consequently a need for desirable ingredients that can provide effective acne management and treatment, that is safe, inexpensive to manufacture and can be applied across a broad range of different skin types.
The inventors have identified that there are obvious advantages and usefulness in using the inventive combinatorial composition in this innovative acne skin treatment. In the first instance, the composition does not cause any side effects. In addition, when applied, it works substantially faster than other acne treatments compositions.
Furthermore, its incorporation is optimised with a combination comprised of other natural ingredients from plants used in traditional medicine and specific selected ingredients.
Moreover, the inventive composition is not restricted in its application because it can be used for skin toning, the calming of skin inflammation; provide moisture for dry skin and as is most effective as an acne vulgaris treatment.
Accordingly, it is an object of the invention to provide a new treatment composition for skin acne vulgaris.
In an embodiment an objective of the invention is to provide an improved skin formulation, which, when applied, works quickly, safely and without any side effects.
The advantages of the invention are clear and in part contain features, properties and related elements which are exemplified in the following disclosure and the scope of the invention and will be indicated in the claims.
The inventors have formulated several compositions of dermatological creams using a specific combination of natural ingredients and selected ingredients in the form of a water-in-oil complex emulsion/suspension, gels or lotions.
The inventors consider that never has such a combination been formulated to help restore and promote natural health maintenance of the skin.
The inventors also consider that the inventive acne formulation is anti-inflammatory and effective to treat skin acne, reduction of redness and control of skin flare ups.
The topical anti-acne composition of the invention comprises and provides a further essential and immediate improvement in skin feel and appearance. It further provides useful visual improvements in skin appearance or conditions following multiple topical applications.
In a further embodiment, the routine includes applying the composition to the surface of the skin in need thereof a safe and effective amount of the said topical composition. The said composition is sufficient to significantly generate a positive benefit on the outlook of skin appearance.
Summary of the innovation According to one aspect of the disclosure, provided are topical botanical compositions.
According to another aspect of the disclosure, provided are topical compositions that inhibit the growth of P. acnes.
According to another aspect of the disclosure, provided are topical compositions that kill P. acnes.
According to another aspect of the disclosure, provided are topical compositions for the control, management, and treatment of acne vulgaris.
According to another aspect of the disclosure, provided are topical compositions that can reduce the formation of whiteheads or blackhead-comedones and inflammatory lesions in the skin.
According to another aspect of the disclosure, provided are topical compositions using conventional extraction methodologies for the preparation of Callistemon viminalis total extract or oils to be used for topical applications for the treatment of acne vulgaris.
According to another aspect of the disclosure, provided are topical compositions using the SFE methodology for the preparation of Callistemon viminalis total extract or oils for inhibiting the growth of P. acnes and thus for topical application for control and management of acne vulgaris. According to another aspect of the disclosure, provided are topical combination of compositions of extracts and oils with a minimum bactericidal concentration for the inhibition of colony forming units (CFU) and killing of P. acnes.
According to another aspect of the disclosure, provided are topical combination comprising of a combination of the said-prepared total plant extract or oils and specifically complementing selected plant extracts or oils and certain ingredients to stop the growth of P. acnes, control of sebum control, soothing and calming of skin inflammation and collectively for the control and treatment of acne vulgaris.
According to another aspect of the disclosure, provided are topical combinations of the said curcumin TA or oils and Callistemon viminalis total extract or oils and other precisely selected plant extracts or oils, and other specifically selected ingredients, as a combination in the form of creams, oils, emulsions, gels, ointments, pomades, soaps, lotions, serums, skin conditioners, skin toner, skin cleansers, for the treatment of acne vulgaris.
Definitions Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
The term "consisting of' will be understood to be exhaustive, excluding non-recited active components of the compositions.
As used herein the terms 'treat' or 'treatment' and variations thereof refer to any and all uses which a remedy for acne vulgaris. Thus, the terms are to be considered in their broadest context. For example, treatment does not essentially imply that a person's skin is treated until total recovery. In conditions which are characterised by necessary to prevent, hinder, retard, or reverse all the said symptoms, but may prevent, hinder, retard, or reverse one or more of said associated symptoms with acne vulgaris.
Detailed description of the preferred embodiments In a most preferred embodiment, the present inventive innovation provides a composition comprised of prepared curcumin TA or oils and preferably total plant extract or oils from the Callistemon viminalis species, other specially selected plant extracts or oils, and specific selected ingredients as a combination for topical application for the treatment of acne vulgaris.
In accordance with another particular embodiment of the disclosure, the composition concentration is between 0.001 mg and 10000 mg weight to volume or a varying percentage range from 0.001 percent and 95 percent volume to volume, with the said total Callistemon viminalis plant extract or oil composition such as general curcumin and c. xanthorrhizaoil, vitellariaparadoxal, salix alba, clove bud oil, camellia sinensis, melaleuca alternifolia, thymus quinquecostatus, niacinamide, salicylic acid, N Acetylcysteine.
The composition will be typically formulated to be suitable for topical administration. By way of example only, the composition may be in the form of an oil, gel, cream, soap, emulsion or -lotion.
Those skilled in the art will appreciate that the application may be varied depending on a variety of factors including, for example, the severity of the acne vulgaris suffered by the subject, the age, general health and diet of the subject, and combination with any other treatment or therapy.
The timing of administration, number of topical administrations, and the duration of administration may be determined by the subject and/or a consulting health professional.
The reference in this specification or information derived from it, or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that the prior art (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
The botanical active ingredients that are used in the topical compositions are useful, safe and suitable for use mammalian usage. In various embodiments, the topical compositions of the disclosure comprise about 0.001% to about 95%, more preferably about 0.05% to approximately 5% of a cumulative amount of the botanical active ingredients such as Callistemon viminalisoil based on a total amount of the topical compositions. (As used herein, all percentages are percentage by weight of the total composition weight, unless otherwise indicated.)
In addition, relative efficacious concentration of active botanical ingredients in the topical compositions depend upon the active compounds in the extract and the required dosing for bioavailability, hence, the concentration may vary so that the topical amount delivered is effective to provide the desired effects, as recognized by one of skill in the art.
The disclosure will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the disclosure.
Examples of the innovation By way of example only, a suitable container with a composition for use in accordance with the present disclosure is outlined below. The following is to be construed as merely an illustrative example of a composition for topical application and not as a limitation of the scope of the disclosure in any way.
Example 1 - A cream with a composition comprising of oils from Callistemon viminalis and curcuma longa, curcuma xanthorrhiza, curcuma longa, vitellariaparadoxa, salix alba, clove bud oil, camellia sinensis, melaleuca alternifolia, thymus quinquecostatus, niacinamide, salicylic acid, and N-Acetylcysteine.
Size - Net weight 30 grams / 0.7 FL. OZ
Ingredients - Purified water, Vitellariaparadoxa,Shea butter, cetereayl alcohol, Callistemon viminalis oil, Curcuma xanthorrhizaoil, Salix alba, niacinamide, salicylic acid, Clove bud oil, Camelliasinensis, Melaleuca alternfolia, Thymus quinquecostatus, N-Acetylcysteine.
Example 2 - A group of teenagers with acne were selected to use the formulation as a topical cream to clear their skin and be free of acne. This was achieved using a protocol of a double-blind, placebo controlled, randomized study for assessing the effect of the present composition invention comprising ingredients in a topical cream and combinations thereof for relieving acne vulgaris and skin inflammation.
The objectives were to assess the effect of the callistemon total extract in a topical cream formulation on symptoms of acne vulgaris using thirty-three (33) individuals (16 females and 14 males), that suffer from acne vulgaris. The cream contained oil, water and total extract, derivatives, and combinations thereof The criteria of this study included individuals suffering from moderate and severe acne vulgaris levels, ranging from the ages of 19-28 years of age. Control creams were also used, and these did not contain any active constituents. The voluntary participants in this study were willing to commit to the application of topical applications of the cream and to complete evaluation and study visits (informed consent). They also agreed not to change the type of creams or increase the frequency of the current application or change or alter any therapies outside the nominated cream application.
Individuals not eligible to be enrolled into this protocol were those that were pregnant or nursing, or of childbearing potential and not practicing an effective means of birth control. Furthermore, exclusions included those having evidence of significant, haematological, endocrine, cardiovascular, coronary, pulmonary, gastrointestinal, or neurological diseases (questionnaire). In addition, individuals with thyroid complications, we excluded, and individuals that suffered from allergies. Individuals applied the topical cream to affected areas of the skin containing acne vulgaris symptoms and subsequently assessed. The cream was applied daily for a duration of 120 hours (5 days).
The study outcomes demonstrated that individuals tolerated the composition well with no adverse reactions. The statistics (p=0.05) demonstrated that the topical cream used resulted in beneficial outcomes in eliminating acne vulgaris. Changes were witnessed on their skin with symptoms totally reduced on day 2 and the elimination of acne removed by day 5. Results also demonstrated that the topical also minimised inflammatory lesions and sebum production, compared to the placebo control. Collectively the topical cream relieved, reduced and eliminated acne vulgaris. Thus, the present invention (i.e., cream formulation), comprising essentially of Callistemon extract and combinations is effective in the reduction and removal of acne according to the protocol. Subjects were subsequently followed up for 2 weeks to ensure safety and beneficial skin outcomes were maintained.
Claims (5)
1. A composition comprising of total plant extract, oil, or water from the Callistemon species, commonly referred to as bottlebrush, with the preferred species as Callistemon citrinusfor use, (a) in a formulation for topical applications to reduce, inhibit or stop the growth of Propionibacteriumacnes, also known as Cutibacteria (b) as a method or composition for the treatment of acne vulgaris in a mammalian subject, (c) in applications as a method of prevention of acne vulgaris.
2. A composition comprising of the said ingredients in claim 1, that further comprises of combining with at least one other plant extract, oil, or water from the genus curcuma with the preferred species curcuma Xanthorrhiza, curcuma longa, vitellaria paradoxa, salix alba, clove bud, Camellia sinensis, Melaleuca alternzfolia, Thymus quinquecostatus, and combinations thereof, in a formulation for topical applications as a method of acne vulgaris treatment.
3. A composition comprising of the said ingredients in claim 1 and claim 2 and combinations thereof, and further comprises of a combination with at least one ofniacinamide, salicylic acid, N Acetylcysteine, or combinations thereof, in a formulation for topical application to the skin as yielding a therapeutic effect for the treatment of acne vulgaris.
4. A composition comprising of the said ingredients from claims 1-3, in a formulation in the form of cream, powder, oil, emulsion, gel, ointment, pomade, soap, lotion, serum, skin conditioner, skin toner, skin cleanser, for topical application to the skin and the said compositions yielding a therapeutic effect on a colony reduction of P. acnes and,
(a) the preferred method of preventing, inhibiting or treatment of acne vulgaris, (b) a method of reducing the formation of whiteheads or blackhead-comedones (c) a method of reducing inflammatory lesions and pustules of the skin,
5. A composition comprising of the said ingredients from claims 1-4 in a formulation and applications as a method of acne vulgaris treatment with an active concentration ranging from 0.001 % to 99 %, weight to volume or volume to volume.
Figure 1. Gas chromatograph of Callistemon citrinus as a chemical signature of the species
A B
Figure 2. Before ((A) and after (B) results of a patient that used the cream composition described in this invention subsequent 120 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021104471A AU2021104471A4 (en) | 2021-07-23 | 2021-07-23 | Botanical Compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021104471A AU2021104471A4 (en) | 2021-07-23 | 2021-07-23 | Botanical Compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021104471A4 true AU2021104471A4 (en) | 2021-09-16 |
Family
ID=77666653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021104471A Active AU2021104471A4 (en) | 2021-07-23 | 2021-07-23 | Botanical Compositions |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021104471A4 (en) |
-
2021
- 2021-07-23 AU AU2021104471A patent/AU2021104471A4/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pundir et al. | Ethnomedicinal uses, phytochemistry and dermatological effects of Hippophae rhamnoides L.: A review | |
| Aghamohammadi et al. | The effectiveness of Zataria extract mouthwash for the management of radiation-induced oral mucositis in patients: A randomized placebo-controlled double-blind study | |
| Fazmiya et al. | Current Insights on Bioactive Molecules, Antioxidant, Anti‐Inflammatory, and Other Pharmacological Activities of Cinnamomum camphora Linn | |
| Chaijan et al. | The myrtus communis L. solution versus ketoconazole shampoo in treatment of dandruff: A double blinded randomized clinical trial | |
| Lueangarun et al. | Clinical efficacy of 0.5% topical mangosteen extract in nanoparticle loaded gel in treatment of mild‐to‐moderate acne vulgaris: A 12‐week, split‐face, double‐blinded, randomized, controlled trial | |
| Lourith et al. | Formulation and clinical evaluation of the standardized Litchi chinensis extract for skin hyperpigmentation and aging treatments | |
| WO2017036241A1 (en) | Acne-removing traditional chinese medicine composition and preparation method thereof | |
| Kumari et al. | Promising essential oils/plant extracts in the prevention and treatment of dandruff pathogenesis | |
| Talebi et al. | Potential of Trachyspermum ammi (ajwain) gel for treatment of facial acne vulgaris: a pilot study with skin biophysical profile assessment and red fluorescence photography | |
| Moutawalli et al. | The biological and pharmacologic actions of Lawsonia inermis L | |
| TWI535449B (en) | Use of plectranthus amboinicus extract for preparing anti-acne composition | |
| Samarh et al. | Evidence based medical use of aloe vera extracts, short review of literature | |
| US8852653B1 (en) | Herbal/organic composition for the management of pain | |
| WO2021058521A1 (en) | A topical plant extract formulation comprising urtica dioica and vitamin a | |
| AU2021104471A4 (en) | Botanical Compositions | |
| US9028888B2 (en) | Compositions and methods for treatment and management of pain | |
| Haniadka et al. | Review on the use of Aloe vera (Aloe) in dermatology | |
| WO2016111477A1 (en) | Cosmetic composition for alleviation or improvement of sebum secretion stimulated by stress, comprising, as active ingredient, extract of carthamus tinctorious l. seed, or mixed extract of carthamus tinctorious l. seed and areca catechu l. seed | |
| AU2014101530A4 (en) | Topical compositions | |
| Kumara et al. | Pharmaceutical, nutritional and cosmetic applications of Aloe vera plant | |
| Youssef | Nigella sativa Seeds in Cosmetic Products: Shedding the Light on the Cosmeceutical Potential of Nigella sativa and its Utilization as a Natural Beauty Care Ingredient | |
| KR100892742B1 (en) | Skin external composition for treating pimple | |
| US20200276256A1 (en) | Skin care composition | |
| Kumar et al. | Cosmeceutical Current Review of Herbal Plants Used for Skin Diseases and Related Problems in India: An Overview: https://doi. org/10.54037/WJPS. 2022.100307 | |
| WO2019209224A2 (en) | Topical compositions for the treatment of dermatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) |